Vyfemla cost?

How much does Vyfemla cost per month?
The list price for a typical 28‑day supply of Vyfemla (veliparib) is around $4,500–$5,000. This estimate assumes the standard dose of 30 mg taken once daily, which is the dosing used in most clinical trials.

What factors can shift that number?
- Insurance coverage: Many plans negotiate discounts or use pharmacy benefit manager (PBM) contracts that can bring the out‑of‑pocket cost down to a few hundred dollars.
- Co‑payment tiers: If the drug falls in a high‑tier specialty category, co‑payments can range from $200–$600 per month.
- Manufacturer coupons or patient assistance: The manufacturer offers a patient assistance program that may cover the full cost for qualifying patients.

Can insurance actually cover Vyfemla?
Yes, most commercial insurers and Medicare Part D plans list Vyfemla as a covered drug. However, the amount reimbursed depends on the specific formulary placement and whether the patient has already used other oncology drugs that trigger step‑downs.

Are there discount programs for patients without insurance?
The manufacturer’s patient assistance program can provide the medication free of charge to patients who meet income and medical criteria. In addition, some non‑profit oncology foundations offer vouchers that cover the cost of specialty drugs.

How does Vyfemla’s price compare with other PARP inhibitors?
- Olaparib (Lynparza): ~$6,000–$7,000 per month.
- Rucaparib (Rubraca): ~$5,500 per month.
- Niraparib (Zejula): ~$4,200 per month.
Vyfemla sits near the lower end of the spectrum, though actual patient costs may vary with insurance and assistance programs.

What happens when the patent expires?
Vyfemla’s patent protection for the 30‑mg formulation is expected to expire in 2027. Once the exclusivity ends, biosimilar or generic versions could enter the market, potentially reducing the list price by 20–40 %.

Will there be a biosimilar or generic?
Manufacturers typically file for a generic version within 18–24 months after patent expiry, depending on regulatory review speed. A generic could be available as early as late 2028.

Is there a cost‑saving strategy for patients on long‑term therapy?
Some patients negotiate a "bulk‑buy" arrangement where a pharmacy orders a full 6‑month supply upfront, which can trigger a higher discount. Discussing this option with the oncology pharmacist can lower the monthly out‑of‑pocket expense.

Where can I find more detailed pricing or assistance details?
DrugPatentWatch provides up‑to‑date price analyses and links to manufacturer assistance programs. See their Vyfemla page for the latest figures and resources.
DrugPatentWatch – Vyfemla Pricing